Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments?

Nature Clinical Practice Oncology volume 4, pages 152–153 (2007)Cite this article

boxed-textBorges S et al. (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80: 61–74

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Stearns V et al. (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95: 1758–1764

    Article  CAS  Google Scholar 

  2. Goetz MP et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23: 9312–9318

    Article  CAS  Google Scholar 

  3. Jin Y et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97: 30–39

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Institute for Drug Development, Cancer Therapy and Research Center, Alice P McDermott Building, 14960 Omicron Drive, San Antonio, TX 78245–3217, USA ctakimot@idd.org

Authors and Affiliations

  1. CH Takimoto is the Director of Pharmacology at the Institute for Drug Development, Cancer Therapy & Research Center, and Clinical Associate Professor at the University of Texas Health Science Center, San Antonio, TX, USA.,

    Chris H Takimoto

Authors
  1. Chris H Takimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Takimoto, C. Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments?. Nat Rev Clin Oncol 4, 152–153 (2007). https://doi.org/10.1038/ncponc0716

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0716

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing